Abstract
In children with acute myeloid leukaemia (AML), assessment of initial treatment response is an essential prognostic factor; methods more sensitive than morphology are still under evaluation. We report on the measurement of minimal residual disease (MRD), by multicolour flow-cytometry in one centralized laboratory, in 142 children with newly diagnosed AML enrolled in the Associazione Italiana di EmatoOncologia Pediatrica-AML 2002/01 trial. At the end of the first induction course, MRD was 1% in 51 patients. The 8-year disease-free survival (DFS) of 125 children in morphological complete remission and with MRD
Original language | English |
---|---|
Pages (from-to) | 116-126 |
Number of pages | 11 |
Journal | British Journal of Haematology |
Volume | 177 |
Issue number | 1 |
DOIs | |
Publication status | Published - Apr 1 2017 |
Keywords
- Acute myeloid leukaemia
- Flow-cytometry
- Minimal residual disease
- Paediatric; Risk group